Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.80 |
| ▸ | LMNA | P02545 | 7/20 | 0.80 |
| ▸ | MAPT | P10636 | 7/20 | 0.80 |
| ▸ | TP53 | P04637 | 5/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.80 |
| ▸ | HTR1A | P08908 | 3/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.80 |
| ▸ | DRD1 | P21728 | 3/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.80 |
| ▸ | DRD3 | P35462 | 3/20 | 0.80 |
| ▸ | THPO | P40225 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612615 | 1.00 | FPR2 (0.80) | FPR2LMNAMAPTTP53MAPK1 | |
| SCHEMBL23353457 | 0.96 | TP53 (0.85) | FPR2LMNAMAPTTP53MAPK1 | |
| Trifluoperazine SCHEMBL28057424 | 0.93 | FPR2 (0.86) | FPR2LMNAMAPTTP53MAPK1 | |
| SCHEMBL26568647 | 0.93 | FPR2 (0.69) | FPR2LMNAMAPTTP53MAPK1 | |
| SCHEMBL23353456 | 0.90 | FPR2 (0.77) | FPR2LMNAMAPTTP53MAPK1 | |
| Trifluoperazine SCHEMBL24866 | 0.89 | FPR2 (1.00) | FPR2LMNAMAPTTP53MAPK1 | |
| Trifluoperazine SCHEMBL1897003 | 0.89 | FPR2 (1.00) | FPR2LMNAMAPTTP53MAPK1 | |
| Trifluoperazine SCHEMBL29603012 | 0.89 | FPR2 (1.00) | FPR2LMNAMAPTTP53MAPK1 | |
| SCHEMBL12431852 | 0.88 | TP53 (0.70) | FPR2LMNAMAPTTP53MAPK1 | |
| Trifluoperazine SCHEMBL23039392 | 0.88 | LMNA (1.00) | FPR2LMNAMAPTTP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-14 | — | — | US | claimed |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20210137938-A1 | NUPR1 INHIBITION FOR TREATING CANCER | UNIVERSITÉ D'AIX-MARSEILLE (FR) | 2021-05-13 | — | — | US | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| WO-2010056979-A1 | PHENOTHIAZINE DERIVATIVES FOR TREATMENT OF ASTHMA | IMMUNE CONTROL, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2010009332-A1 | BINDING AND INHIBITING 5-HT4 RECEPTOR | IMMUNE CONTROL, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IL5, HRH4, TLR5 | FPR2 80/4885LMNA 3774/4885MAPT 1538/4885 |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | HTR4, HTR3B, HTR5A | FPR2 70/4885LMNA 4056/4885MAPT 3747/4885 |
| US-20230330095-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP50, NUP188 | FPR2 4687/4885LMNA 236/4885MAPT 2789/4885 |
| US-20210137938-A1 | NUPR1 INHIBITION FOR TREATING CANCER | NUP188, NUP160, NUP50 | FPR2 1254/4885LMNA 199/4885MAPT 1395/4885 |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | FPR2 43/4885LMNA 1395/4885MAPT 2358/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | FPR2 153/4885LMNA 301/4885MAPT 3914/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | FPR2 47/4885LMNA 1482/4885MAPT 2819/4885 |
| US-20250255879-A1 | PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR | NUP205, NUP188, NUP50 | FPR2 4728/4885LMNA 171/4885MAPT 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.